semaglutide injection fda approval Ozempic® GLP for Weight Loss FDA approves Ozempic to reduce

Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer

If more than 5 days have passed, skip the missed dose and resume on your next scheduled day

Accessed March 9, 2026.

Angewandte Chemie International Edition in English

In a significant milestone for type 2 diabetes care, Novo Nordisk has unveiled full results from its SOUL cardiovascular outcomes trial, confirming that oral semaglutide (14 mg) reduces the risk of major adverse cardiovascular events (MACE) by 14 per cent compared to placebo in adults with type 2 diabetes and existing cardiovascular and/or chronic kidney disease